Hualan Biological Engineering Inc. (SHE:002007)

Market Cap	29.33B
Revenue (ttm)	4.52B
Net Income (ttm)	1.16B
Shares Out	1.83B
EPS (ttm)	0.64
PE Ratio	25.19
Forward PE	20.76
Dividend	0.50 (3.12%)
Ex-Dividend Date	Jun 17, 2025

Volume	9,115,806
Average Volume	18,477,312
Open	16.29
Previous Close	16.06
Day's Range	15.92 - 16.29
52-Week Range	14.72 - 19.70
Beta	0.37
RSI	36.31
Earnings Date	Oct 30, 2025

About SHE:002007

Hualan Biological Engineering Inc. researches, develops, produces, and commercializes blood products, vaccines, and genetic engineering products in China and internationally. The company offers human serum albumin to treat blood loss trauma, shock caused by burns, intracranial pressure and persistent, liver cirrhosis, and kidney disease; edema for hypoproteinemia, neonatal hyperbilirubinemia, cardiopulmonary bypass, adjuvant treatment of burns, hemodialysis, and human respiratory distress syndrome; intravenous human immunoglobulin (pH4) for imm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 4,012
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002007

Financial Performance

In 2024, SHE:002007's revenue was 4.38 billion, a decrease of -18.02% compared to the previous year's 5.34 billion. Earnings were 1.09 billion, a decrease of -26.57%.